Clinical trial
A Phase IIa Open Label Study to Evaluate the Safety, Tolerability and Efficacy of S-1226 Administered by Nebulization in Subjects With Mild to Moderate Cystic Fibrosis and Non CF Bronchiectasis
NCT03903913 is registered in ClinicalTrials.gov with SolAeroMed Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IIa Open Label Study to Evaluate the Safety, Tolerability and Efficacy of S-1226 Administered by Nebulization in Subjects With Mild to Moderate Cystic Fibrosis and Non CF Bronchiectasis
- Lead sponsor
- SolAeroMed Inc.
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- August 8, 2019
- Completion date
- August 31, 2022
- Enrollment
- 12 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.